Boston Scientific Embol-X Buy Readies Firm For Carotid Stent Race
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's acquisition of embolic protection technology developed by Embol-X may help level the playing field with competitors Guidant and Johnson & Johnson in the race to bring carotid stent technology to market.
You may also be interested in...
Edwards Enters Embolic Filtration Market With Embol-X Technology
Edwards Lifesciences will offer embolic filtration technology developed by Embol-X, Inc. for use during open-heart procedures such as valve replacement under an asset purchase valued at about $10 mil
Edwards Enters Embolic Filtration Market With Embol-X Technology
Edwards Lifesciences will offer embolic filtration technology developed by Embol-X, Inc. for use during open-heart procedures such as valve replacement under an asset purchase valued at about $10 mil
Boston Scientific Gains Distal Protection Market Entry With EPI's Filterwire
Boston Scientific's $75 mil. acquisition of Embolic Protection, Inc. provides an immediate entry into the vascular distal protection market.